Tempus AI Secures Major ARPA-H Contract for Precision Cancer Therapy Program

Tempus AI Secures Significant Contract with ARPA-H for Advanced Cancer Therapy

Tempus AI (NASDAQ: TEM), a technology company specializing in the application of artificial intelligence to advance precision medicine, has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services. This selection positions Tempus AI to provide testing and contract research organization (CRO) services for the ADAPT (Advanced Analysis for Precision Cancer Therapy) program. The ADAPT program is designed to revolutionize cancer treatment by developing adaptive strategies that leverage biomarkers, computational models, and innovative clinical trial designs, initially focusing on non-small cell lung, breast, and colorectal cancers.

Details of the ADAPT Program Collaboration

Under the terms of the contract, Tempus AI will play a pivotal role in the ADAPT program by offering access to its comprehensive portfolio of AI-enabled diagnostics, including xE, xR, xF+, and xM. Additionally, its CRO services, Compass, will manage trial operations across all participating sites. The company will also utilize its expertise in data integration to collect and harmonize study data on behalf of the program. The competitively awarded contract is valued at $60.57 million and includes Firm-Fixed-Price and Time-and-Materials line items. The period of performance for this contract commenced on September 18, 2025, and is slated to conclude on September 17, 2030.

Eric Lefkofsky, Founder and CEO of Tempus, underscored the company's distinctive capabilities:

"Tempus is proud to work with ARPA-H on the ADAPT program, which is pioneering a new era of cancer care designed to adapt throughout treatment. With our comprehensive molecular profiling, data integration expertise, and CRO services all in one place, Tempus is uniquely positioned to advance this effort. We look forward to helping ARPA-H deliver more precise, personalized treatments that benefit each patient."

Market Reaction and Strategic Implications

The award of this substantial contract is anticipated to generate a bullish sentiment for Tempus AI and impart positive implications across the broader AI in healthcare and biotechnology sectors. This collaboration serves as a significant validation of Tempus AI's technology and strategically expands its market reach within the healthcare landscape. Furthermore, it signals a broader trend of government agencies increasing investments in advanced AI and data integration solutions for critical health initiatives, potentially bolstering investor confidence in the entire AI healthcare sector.

This development follows a period of notable growth and strategic maneuvering for Tempus AI. The company reported a significant improvement in its second-quarter 2025 financial results, with adjusted EBITDA reaching ($5.6 million), marking a $25.6 million enhancement from the previous year. Revenue growth for Q2 2025 was nearly 90% year-over-year, driven by a 115% surge in its Genomics segment and a 35.7% increase in Data and Services. The company has also raised its full-year 2025 revenue guidance to $1.26 billion and projects full-year adjusted EBITDA to reach $5 million.

Earlier in 2025, Tempus AI expanded its strategic partnerships with AstraZeneca and Pathos AI, securing $200 million in data licensing and model development fees, which led to a 14.5% jump in its shares. The company has also made key acquisitions, including Paige for $81.25 million in August 2025 to enhance its digital pathology capabilities, and Deep 6 AI in March 2025 to bolster clinical trial recruitment. These moves, coupled with the acquisition of Ambry Genetics, underscore Tempus AI's aggressive strategy to consolidate high-quality data, AI competency, and clinical reach.

Broader Sector Context and Future Outlook

This contract positions Tempus AI at the forefront of the burgeoning precision medicine landscape and the accelerating adoption of AI in healthcare. The global oncology market is projected to grow at a compound annual growth rate (CAGR) of 35.51% from 2025 to 2030, with an anticipated market volume of $9.04 billion by 2030. Tempus AI's integrated strategy—combining government contracts, strategic partnerships, and targeted acquisitions—positions it as a dominant force in leveraging AI for oncology solutions.

Looking ahead, investors and industry observers will be closely monitoring the progress of the ADAPT program, Tempus AI's continued financial performance, and any further government or industry partnerships that may arise in the rapidly evolving AI healthcare space. The company's ability to consistently execute on its stated mission of advancing precision medicine through AI will be a critical determinant of its long-term growth trajectory and market valuation.